<p>Rezdiffra is a medicine used together with diet and physical activity to treat adults with metabolic dysfunction-associated steatohepatitis (MASH). MASH (also known as NASH, non-alcoholic steatohepatitis) is a disease caused by fat building up in the liver, resulting in inflammation and damage to the liver. Rezdiffra is used in adults with moderate or significant scarring of the liver (stage 2 or stage 3 fibrosis).</p><p>Rezdiffra contains the active substance resmetirom.</p>
Therapeutic Indication
<div class="subsection mt-3-5"> <h3>Therapeutic indication</h3><p>Rezdiffra is indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis (fibrosis stages F2 to F3).</p></div>
Therapeutic Area (MeSH)
ATC Code
A05
ATC Item
N/A
Pharmacotherapeutic Group
Bile and liver therapy
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| resmetirom | N/A | resmetirom |
EMA Name
Rezdiffra
Medicine Name
Rezdiffra
Aliases
N/ANo risk management plan link.
